Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 110

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 110
---
 (since August 13, 2024)                      Francois Michelon   2024  202,126   -   -   112,524(4)  314,650 Former Chief Executive Officer (until August 12, 2024) 2023  387,859   258,341   -   587   646,787 Michael Thornton (5) 2024  221,690   -   -   392   222,082 Chief Technology Officer 2023  278,851   252,734   -   392   531,977 Richard Jacroux 2024  95,900   -   -   -   95,900(6)Chief Financial Officer (since August 8, 2024)                      Irina Pestrikova 2024  126,298   -   -   -   126,298 Former Senior Director, Finance (until August 8, 2024) 2023  185,000   29,724   -   -   214,724 

______________

(1) The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see notes 2 and 8 to the financial statements included in Part II, Item 8 of this Annual Report. The shares underlying these option awards vest and become exercisable in three equal annual installments beginning on the first anniversary of their respective grant dates.(2) Represents insurance premiums paid by the Company with respect to life insurance for the benefit of the named executive officer, unless footnoted otherwise.

(3) Prior to appointment as Acting Chief Executive Officer, Mr. Tokman served on the Board and provided consulting services to the Company.  As a Board member, in January 2024, he was awarded an annual option grant to purchase 600 shares with a per share exercise price of $1.59.  This grant was subject to adjustment due to the Company’s August 2024 Reverse Stock Split and the November 2024 Reverse Stock Split.  After adjustment, this grant is for 1 share with a per share exercise price of $2,782.50.  The amount